Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema
Status:
Terminated
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label study designed to evaluate the long-term safety of prophylactic
avoralstat (500 mg three times daily) when given to approximately 150 patients with
hereditary angioedema (HAE) for a duration of up to 72 weeks. The study will also evaluate
the long-term efficacy and impact on quality of life of avoralstat prophylactic treatment.